{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T00:19:49Z","timestamp":1760746789781,"version":"build-2065373602"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-025-11773-x","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T11:31:24Z","timestamp":1760700684000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk factors of COVID-19 breakthrough infection: a case-control test-negative design study"],"prefix":"10.1186","volume":"25","author":[{"given":"Gabriela","family":"Tejada-Panduro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laia","family":"Pin\u00f3s-Tella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susana","family":"Otero-Romero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blanca","family":"Borras-Bermejo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid","family":"Carbones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9s","family":"Ant\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Andr\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oleguer","family":"Par\u00e9s-Badell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"key":"11773_CR1","unstructured":"World Health Organization. COVID-19 Weekly Epidemiological Update. 2022 Dec."},{"key":"11773_CR2","unstructured":"Ritchie H, Mathieu E, Rod\u00e9s-Guirao L, Appel C, Giattino C, Ortiz-Ospina E. Coronavirus (COVID-19) Vaccinations - Our World in Data. [cited 2023 Jan 2]. Available from: https:\/\/ourworldindata.org\/covid-vaccinations."},{"key":"11773_CR3","unstructured":"Instituto de Estad\u00edstica de Catalu\u00f1a. Vacunaci\u00f3n del Covid-19 [Internet]. 2022 [cited 2023 May 2]. Available from: https:\/\/www.idescat.cat\/indicadors\/?lang=es&id=conj&n=14357."},{"key":"11773_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.23937","author":"X Han","year":"2021","unstructured":"Han X, Xu P, Ye Q. Analysis of COVID-19 vaccines: types, thoughts, and application. J Clin Lab Anal. 2021. https:\/\/doi.org\/10.1002\/jcla.23937.","journal-title":"J Clin Lab Anal"},{"issue":"23","key":"11773_CR5","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","volume":"384","author":"J Sadoff","year":"2021","unstructured":"Sadoff J, Gray G, Vandebosch A, C\u00e1rdenas V, Shukarev G, Grinsztejn B, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med. 2021;384(23):2187\u2013201.","journal-title":"N Engl J Med"},{"issue":"10269","key":"11773_CR6","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","volume":"397","author":"M Voysey","year":"2021","unstructured":"Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99\u2013111.","journal-title":"Lancet"},{"issue":"19","key":"11773_CR7","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1056\/NEJMoa2113017","volume":"385","author":"HM el Sahly","year":"2021","unstructured":"el Sahly HM, Baden LR, Essink B, Doblecki-Lewis S, Martin JM, Anderson EJ, et al. Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. N Engl J Med [Internet]. 2021;385(19):1774\u201385 2021 Nov 4 [cited 2023 Jan 2];Available from: https:\/\/www.pmc\/articles\/PMC8482810\/.","journal-title":"N Engl J Med [Internet]"},{"issue":"27","key":"11773_CR8","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603\u201315.","journal-title":"N Engl J Med"},{"issue":"25","key":"11773_CR9","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1056\/NEJMoa2105290","volume":"385","author":"AR Falsey","year":"2021","unstructured":"Falsey AR, Sobieszczyk ME, Hirsch I, Sproule S, Robb ML, Corey L, et al. Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine. N Engl J Med. 2021;385(25):2348\u201360 https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2105290.","journal-title":"N Engl J Med"},{"issue":"10287","key":"11773_CR10","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(21)00947-8","volume":"397","author":"EJ Haas","year":"2021","unstructured":"Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using National surveillance data. Lancet. 2021;397(10287):1819\u201329.","journal-title":"Lancet"},{"issue":"20","key":"11773_CR11","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.19499","volume":"326","author":"MW Tenforde","year":"2021","unstructured":"Tenforde MW, Self WH, Adams K, Gaglani M, Ginde AA, McNeal T, et al. Association between mrna vaccination and COVID-19 hospitalization and disease severity. JAMA. 2021;326(20):1.","journal-title":"JAMA"},{"key":"11773_CR12","doi-asserted-by":"crossref","unstructured":"Lopez Bernal J, Andrews N, Gower C, Robertson C, Stowe J, Tessier E, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on COVID-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ. 2021;373:n1088.","DOI":"10.1136\/bmj.n1088"},{"issue":"15","key":"11773_CR13","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1056\/NEJMoa2110362","volume":"385","author":"MG Thompson","year":"2021","unstructured":"Thompson MG, Stenehjem E, Grannis S, Ball SW, Naleway AL, Ong TC, et al. Effectiveness of Covid-19 vaccines in ambulatory and inpatient care settings. N Engl J Med. 2021;385(15):1355\u201371.","journal-title":"N Engl J Med"},{"issue":"19","key":"11773_CR14","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1056\/NEJMoa2110345","volume":"385","author":"SJ Thomas","year":"2021","unstructured":"Thomas SJ, Moreira ED, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. N Engl J Med. 2021;385(19):1761\u201373.","journal-title":"N Engl J Med"},{"issue":"10328","key":"11773_CR15","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S0140-6736(22)00152-0","volume":"399","author":"DR Feikin","year":"2022","unstructured":"Feikin DR, Higdon MM, Abu-Raddad LJ, Andrews N, Araos R, Goldberg Y, et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet. 2022;399(10328):924\u201344.","journal-title":"Lancet"},{"key":"11773_CR16","doi-asserted-by":"crossref","unstructured":"Team CC 19 VBCI, Team CC 19, Birhane VBCI, Bressler M, Chang S, Clark G. T, COVID-19 Vaccine Breakthrough Infections Reported to CDC \u2014 United States, January 1\u2013April 30, 2021. Morbidity and Mortality Weekly Report. 2021;70(21):792. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC8158893\/. Cited 2023 Jan 2.\u00a0","DOI":"10.15585\/mmwr.mm7021e3"},{"issue":"5","key":"11773_CR17","doi-asserted-by":"publisher","first-page":"79","DOI":"10.5501\/wjv.v9.i5.79","volume":"9","author":"S SeyedAlinaghi","year":"2020","unstructured":"SeyedAlinaghi S, Oliaei S, Kianzad S, Afsahi AM, MohsseniPour M, Barzegary A, et al. Reinfection risk of novel coronavirus (COVID-19): A systematic \u200ereview of current evidence. World J Virol. 2020;9(5):79.","journal-title":"World J Virol"},{"key":"11773_CR18","doi-asserted-by":"crossref","unstructured":"Gopinath S, Ishak A, Dhawan N, Poudel S, Shrestha PS, Singh P et al. Characteristics of COVID-19 breakthrough infections among vaccinated individuals and associated risk factors: A systematic review. Trop Med Infect Dis. 2022;7(5).","DOI":"10.3390\/tropicalmed7050081"},{"issue":"15","key":"11773_CR19","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1016\/j.vaccine.2023.02.038","volume":"41","author":"PD Smits","year":"2023","unstructured":"Smits PD, Gratzl S, Simonov M, Nachimuthu SK, Goodwin Cartwright BM, Wang MD, et al. Risk of COVID-19 breakthrough infection and hospitalization in individuals with comorbidities. Vaccine. 2023;41(15):2447\u201355.","journal-title":"Vaccine"},{"issue":"1","key":"11773_CR20","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S1473-3099(21)00460-6","volume":"22","author":"M Antonelli","year":"2022","unstructured":"Antonelli M, Penfold RS, Merino J, Sudre CH, Molteni E, Berry S, et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID symptom study app: a prospective, community-based, nested, case-control study. Lancet Infect Dis. 2022;22(1):43\u201355.","journal-title":"Lancet Infect Dis"},{"key":"11773_CR21","doi-asserted-by":"crossref","unstructured":"Vivaldi G, Jolliffe DA, Holt H, Tydeman F, Talaei M, Davies GA et al. Risk factors for SARS-CoV-2 infection after primary vaccination with ChAdOx1 nCoV-19 or BNT162b2 and after booster vaccination with BNT162b2 or mRNA-1273: A population-based cohort study (COVIDENCE UK). Lancet Reg Health Europe. 2022;22.","DOI":"10.1016\/j.lanepe.2022.100501"},{"issue":"4","key":"11773_CR22","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s15010-022-01758-2","volume":"50","author":"A Parameswaran","year":"2022","unstructured":"Parameswaran A, Apsingi S, Eachempati KK, Dannana CS, Jagathkar G, Iyer M, et al. Incidence and severity of COVID-19 infection post-vaccination: a survey among Indian Doctors. Infection. 2022;50(4):889\u201395.","journal-title":"Infection"},{"key":"11773_CR23","doi-asserted-by":"crossref","unstructured":"Alishaq M, Nafady-Hego H, Jeremijenko A, Al Ajmi JA, Elgendy M, Vinoy S et al. Risk factors for breakthrough SARS-CoV-2 infection in vaccinated healthcare workers. PLoS ONE. 2021;16(10).","DOI":"10.1371\/journal.pone.0258820"},{"issue":"9","key":"11773_CR24","doi-asserted-by":"publisher","first-page":"e2233446","DOI":"10.1001\/jamanetworkopen.2022.33446","volume":"5","author":"V Nafilyan","year":"2022","unstructured":"Nafilyan V, Ward IL, Robertson C, Sheikh A. Evaluation of risk factors for postbooster Omicron COVID-19 deaths in England. JAMA Netw Open. 2022;5(9):e2233446\u20132233446.","journal-title":"JAMA Netw Open"},{"key":"11773_CR25","doi-asserted-by":"crossref","unstructured":"Suleyman G, Fadel R, Brar I, Kassab R, Khansa R, Sturla N et al. Risk factors associated with hospitalization and death in COVID-19 breakthrough infections. Open Forum Infect Dis. 2022;9(5).","DOI":"10.1093\/ofid\/ofac116"},{"key":"11773_CR26","doi-asserted-by":"crossref","unstructured":"Ben Fredj S, Ghammem R, Zammit N, Maatouk A, Haddad N, Haddad N et al. Risk factors for severe Covid-19 breakthrough infections: an observational longitudinal study. BMC Infect Dis. 2022;22(1).","DOI":"10.1186\/s12879-022-07859-5"},{"key":"11773_CR27","doi-asserted-by":"crossref","unstructured":"Taylor CA, Whitaker M, Patton ME, Melgar M, Kirley PD, Kawasaki B et al. Trends in COVID-19\u2013Attributable Hospitalizations Among Adults With Laboratory\u2010Confirmed SARS\u2010CoV\u20102\u2014COVID\u2010NET, June 2020 to September 2023. Influenza Other Respir Viruses [Internet]. 2024 Nov 1 [cited 2025 Feb 12];18(11):e70021. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11534501\/.","DOI":"10.1111\/irv.70021"},{"key":"11773_CR28","unstructured":"Ministerio de Sanidad. Estrategia de vacunaci\u00f3n frente a la COVID-19 en Espa\u00f1a. Actualizaci\u00f3n 1. Madrid: Gobierno de Espa\u00f1a; 2020 [cited 2025 Feb 12]. Available from: https:\/\/www.sanidad.gob.es\/areas\/promocionPrevencion\/vacunaciones\/covid19\/Actualizaciones_Estrategia_Vacunacion\/docs\/COVID-19_EstrategiaVacunacion.pd."},{"key":"11773_CR29","unstructured":"European Centre for Disease Prevention and Control. Data on SARS-CoV-2 variants in the EU\/EEA 2022. [Internet]. 2023 [cited 2023 Apr 17]. Available from: https:\/\/www.ecdc.europa.eu\/en\/publications-data\/data-virus-variants-covid-19-eueea."},{"issue":"1","key":"11773_CR30","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1056\/NEJMoa2203965","volume":"387","author":"HN Altarawneh","year":"2022","unstructured":"Altarawneh HN, Chemaitelly H, Ayoub HH, Tang P, Hasan MR, Yassine HM, et al. Effects of previous infection and vaccination on symptomatic Omicron infections. N Engl J Med. 2022;387(1):21\u201334.","journal-title":"N Engl J Med"},{"issue":"8","key":"11773_CR31","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1093\/infdis\/jiac161","volume":"226","author":"M \u0160m\u00edd","year":"2022","unstructured":"\u0160m\u00edd M, Berec L, P\u0159ibylov\u00e1 L, M\u00e1jek O, Pavl\u00edk T, Jarkovsk\u00fd J, et al. Protection by vaccines and previous infection against the Omicron variant of severe acute respiratory syndrome coronavirus 2. J Infect Dis. 2022;226(8):1385\u201390.","journal-title":"J Infect Dis"},{"issue":"2","key":"11773_CR32","first-page":"2","volume":"29","author":"ST Tan","year":"2023","unstructured":"Tan ST, Kwan AT, Rodr\u00edguez-Barraquer I, Singer BJ, Park HJ, Lewnard JA, et al. Infectiousness of SARS-CoV-2 breakthrough infections and reinfections during the Omicron wave. Nat Med 2023. 2023;29(2):2.","journal-title":"Nat Med 2023"},{"key":"11773_CR33","doi-asserted-by":"crossref","unstructured":"Bytyci J, Ying Y, Lee LYW. Immunocompromised individuals are at increased risk of COVID-19 breakthrough infection, hospitalization, and death in the post-vaccination era: a systematic review. Immun Inflamm Dis. 2024;12:e1062.","DOI":"10.1002\/iid3.1259"},{"issue":"5","key":"11773_CR34","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1038\/s41591-022-01753-y","volume":"28","author":"HF Tseng","year":"2022","unstructured":"Tseng HF, Ackerson BK, Luo Y, Sy LS, Talarico CA, Tian Y, et al. Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and delta variants. Nat Med. 2022;28(5):1063\u201371.","journal-title":"Nat Med"},{"issue":"9","key":"11773_CR35","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/S1473-3099(22)00292-4","volume":"22","author":"S Monge","year":"2022","unstructured":"Monge S, Rojas-Benedicto A, Olmedo C, Mazagatos C, Jos\u00e9 Sierra M, Limia A, et al. Effectiveness of mRNA vaccine boosters against infection with the SARS-CoV-2 Omicron (B.1.1.529) variant in Spain: a nationwide cohort study. Lancet Infect Dis. 2022;22(9):1313.","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"11773_CR36","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1111\/irv.13026","volume":"16","author":"C Mazagatos","year":"2022","unstructured":"Mazagatos C, Delgado-Sanz C, Monge S, Pozo F, Oliva J, Sandonis V, et al. COVID-19 vaccine effectiveness against hospitalization due to SARS-CoV-2: a test-negative design study based on severe acute respiratory infection (SARI) sentinel surveillance in Spain. Influenza Other Respir Viruses. 2022;16(6):1014\u201325.","journal-title":"Influenza Other Respir Viruses"},{"key":"11773_CR37","doi-asserted-by":"crossref","unstructured":"Buchan SA, Chung H, Brown KA, Austin PC, Fell DB, Gubbay JB et al. Effectiveness of COVID-19 vaccines against Omicron or delta infection. MedRxiv. 2022;2021.12.30.21268565.","DOI":"10.1101\/2021.12.30.21268565"},{"key":"11773_CR38","unstructured":"Ministerio de Sanidad, Febrero. 8, 2022. 2022 [cited 2023 Nov 4]. Actualizaci\u00f3n 11 \u2013 Estrategia de vacunaci\u00f3n COVID-19. Available from: https:\/\/www.sanidad.gob.es\/areas\/promocionPrevencion\/vacunaciones\/covid19\/Actualizaciones_Estrategia_Vacunacion\/docs\/COVID-19_Actualizacion11_EstrategiaVacunacion.pdf."},{"issue":"23","key":"11773_CR39","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1056\/NEJMoa2118946","volume":"386","author":"Y Goldberg","year":"2022","unstructured":"Goldberg Y, Mandel M, Bar-On YM, Bodenheimer O, Freedman LS, Ash N, et al. Protection and waning of natural and hybrid immunity to SARS-CoV-2. N Engl J Med. 2022;386(23):2201\u201312.","journal-title":"N Engl J Med"},{"key":"11773_CR40","doi-asserted-by":"crossref","unstructured":"Ferdinands JM, Rao S, Dixon BE, Mitchell PK, Desilva MB, Irving SA et al. Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study. BMJ. 2022;379.","DOI":"10.1136\/bmj-2022-072141"},{"issue":"1","key":"11773_CR41","first-page":"1","volume":"12","author":"B Mizrahi","year":"2021","unstructured":"Mizrahi B, Lotan R, Kalkstein N, Peretz A, Perez G, Ben-Tov A, et al. Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine. Nat Commun 2021. 2021;12(1):1.","journal-title":"Nat Commun 2021"},{"issue":"11","key":"11773_CR42","doi-asserted-by":"publisher","first-page":"e778","DOI":"10.1016\/S2665-9913(21)00222-8","volume":"3","author":"L Boekel","year":"2021","unstructured":"Boekel L, Steenhuis M, Hooijberg F, Besten YR, van Kempen ZLE, Kummer LY, et al. Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the netherlands: a substudy of data from two prospective cohort studies. Lancet Rheumatol. 2021;3(11):e778\u201388.","journal-title":"Lancet Rheumatol"},{"issue":"5","key":"11773_CR43","doi-asserted-by":"publisher","first-page":"e35311","DOI":"10.2196\/35311","volume":"8","author":"C Liu","year":"2022","unstructured":"Liu C, Lee J, Ta C, Soroush A, Rogers JR, Kim JH, et al. Risk factors associated with SARS-CoV-2 breakthrough infections in fully mRNA-Vaccinated individuals: retrospective analysis. JMIR Public Health Surveill. 2022;8(5):e35311\u201335311.","journal-title":"JMIR Public Health Surveill"},{"issue":"11","key":"11773_CR44","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.7326\/M21-1757","volume":"174","author":"P Deepak","year":"2021","unstructured":"Deepak P, Kim W, Paley MA, Yang M, Carvidi AB, Demissie EG, et al. Effect of immunosuppression on the immunogenicity of mRNA vaccines to SARS-CoV-2: A prospective cohort study. Ann Intern Med. 2021;174(11):1572\u201385.","journal-title":"Ann Intern Med"},{"key":"11773_CR45","doi-asserted-by":"crossref","unstructured":"Bahremand T, Yao JA, Mill C, Piszczek J, Grant JM, Smolina K. COVID-19 hospitalisations in immunocompromised individuals in the Omicron era: a population-based observational study using surveillance data in British Columbia, Canada. Lancet Reg Health Americas. 2023;20.","DOI":"10.1016\/j.lana.2023.100461"},{"issue":"44","key":"11773_CR46","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.15585\/mmwr.mm7044e3","volume":"70","author":"PJ Embi","year":"2021","unstructured":"Embi PJ, Levy ME, Naleway AL, Patel P, Gaglani M, Natarajan K, et al. Effectiveness of 2-dose vaccination with mRNA COVID-19 vaccines against COVID-19\u2013associated hospitalizations among immunocompromised adults \u2014 nine states, January\u2013September 2021. MMWR Morb Mortal Wkly Rep. 2021;70(44):1553.","journal-title":"MMWR Morb Mortal Wkly Rep"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11773-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-11773-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11773-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T11:31:35Z","timestamp":1760700695000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-025-11773-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["11773"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-11773-x","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,17]]},"assertion":[{"value":"20 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The present study was approved by the Human Research Ethics Committee of the Hospital Universitari Vall d\u2019Hebron (approval code: EOM(AG)041\/2022(6030)). The need for consent to participate was waived by this institution. All procedures performed in this study were conducted in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1346"}}